AIP
VIRX

Ameritas Investment Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Ameritas Investment Partners’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,843
Closed -$14K – 3272
2022
Q1 		$14K Hold
2,843
– – ﹤0.01% 2696
2021
Q4 		$10K Hold
2,843
– – ﹤0.01% 2910
2021
Q3 		$23K Hold
2,843
– – ﹤0.01% 2631
2021
Q2 		$32K Buy
+2,843
New +$28.5K ﹤0.01% 2470

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Ameritas Investment Partners's VIRX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 2,843 shares — an estimated $14K sold.

Ameritas Investment Partners first reported a position in VIRX in Q2 2021 and held it in 4 quarters. The position peaked at $32K in Q2 2021. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 2,843 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $14K.
  • Ameritas Investment Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Ameritas Investment Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $32K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.